[시장보고서]암 지지요법제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

암 지지요법제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

Cancer Supportive Care Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

상품코드 : 1442870

리서치사 : Transparency Market Research

발행일 : 2024년 01월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,424,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,785,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,146,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

암 지지요법제 시장 - 보고서 범위

TMR의 세계 암 지지요법제 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻을 수 있는 기회를 연구하고 있습니다. 이 보고서는 전 세계 암 지지요법제의 수익을 제공합니다. 2023년을 기준 연도로, 2031년을 예측 연도로 간주하여 2017년부터 2031년까지의 시장을 분석합니다. 이 보고서는 또한 2023년부터 2031년까지 세계 암 지지요법제 시장의 복합 연간 성장률(CAGR %)을 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 애널리스트가 인터뷰하는 방식으로 대부분의 조사 활동이 이루어졌습니다. 2차 조사에는 암 지지요법제 시장을 이해하기 위해 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조가 포함됩니다.

이 보고서는 세계 암 지지요법제 시장의 경쟁 구도에 대해 자세히 조사하고 있습니다. 세계 암 지지요법제 시장에서 활동하는 주요 기업이 확인되었으며, 각 기업은 다양한 속성 측면에서 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 암 지지요법제 시장의 기업 속성입니다.

소개와 정의
주요 조사 결과/발전
약제 클래스별 시장 금액 예측, 2017-2031년
- G-CSF(과립구집락자극인자)
- ESA(적혈구 생성 자극제)
- 제토제
- 비스포스포네이트
- 오피오이드
- NSAID(비스테로이드성 항염증제)
- 기타(국소제 등)
약제 클래스별 시장 매력

제7장 세계 시장 분석과 예측 : 적응증별

소개와 정의
주요 조사 결과/발전
적응증별 시장 금액 예측, 2017-2031년
- 폐암
- 유방암
- 전립선암
- 간암
- 방광암
- 백혈병
- 기타(난소암, 흑색종 등)
적응증별 시장 매력도

제8장 세계 시장 분석과 예측 : 유통 채널별

소개와 정의
주요 조사 결과/발전
유통 채널별 시장 금액 예측, 2017-2031년
- 병원 약국
- 소매 약국
- 기타(조제 약국 등)
유통 채널별 시장 매력도

제9장 세계 시장 분석과 예측 : 지역별

주요 조사 결과
지역별 시장 금액 예측
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
국가·지역별 시장 매력도

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 예측

제14장 중동 및 아프리카 시장 분석과 예측

제15장 경쟁 상황

시장 기업 - 경쟁 매트릭스(기업 계층 및 규모별)
기업별 시장 점유율 분석(2022년)
기업 개요
- Amgen, Inc.
- Merck &Co., Inc.
- Johnson & Johnson Services, Inc.
- Heron Therapeutics, Inc.
- Novartis AG
- GSK plc
- F. Hoffmann-La Roche Ltd.
- Helsinn Healthcare SA

KSM

영문 목차

영문목차

Cancer Supportive Care Drugs Market - Scope of Report

TMR's report on the global cancer supportive care drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cancer supportive care drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer supportive care drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cancer supportive care drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cancer supportive care drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cancer supportive care drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cancer supportive care drugs market.

The report delves into the competitive landscape of the global cancer supportive care drugs market. Key players operating in the global cancer supportive care drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cancer supportive care drugs market profiled in this report.

Key Questions Answered in Global cancer supportive care drugs market Report:

What is the sales/revenue generated by wearable injectors across all regions during the forecast period?
What are the opportunities in the global cancer supportive care drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Cancer Supportive Care Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global cancer supportive care drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cancer supportive care drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cancer supportive care drugs market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Supportive Care Drugs Market

4. Market Overview

4.1. Introduction
- 4.1.1. Drug Class Definition
- 4.1.2. Industry Evolution/ Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
- 4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter's Five Force Analysis

5. Key Insights

5.1. Key Drug Class/Brand Analysis
5.2. Top 3 Players Operating in the Market Space
5.3. Disease Prevalence and Incidence
5.4. COVID Impact Analysis

6. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Drug Class

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Class, 2017-2031
- 6.3.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
- 6.3.2. ESAs (Erythropoiesis Stimulating Agent)
- 6.3.3. Antiemetics
- 6.3.4. Bisphosphonates
- 6.3.5. Opioids
- 6.3.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- 6.3.7. Others (Topicals, etc.)
6.4. Market Attractiveness By Drug Class

7. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Indication

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication, 2017-2031
- 7.3.1. Lung Cancer
- 7.3.2. Breast Cancer
- 7.3.3. Prostate Cancer
- 7.3.4. Liver Cancer
- 7.3.5. Bladder Cancer
- 7.3.6. Leukemia
- 7.3.7. Others (Ovarian Cancer, Melanoma, etc.)
7.4. Market Attractiveness By Indication

8. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2017-2031
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Others (Compounding Pharmacies, etc.)
8.4. Market Attractiveness By Distribution Channel

9. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Region

9.1. Key Findings
9.2. Market Value Forecast By Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region

10. North America Cancer Supportive Care Drugs Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast By Drug Class, 2017-2031
- 10.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
- 10.2.2. ESAs (Erythropoiesis Stimulating Agent)
- 10.2.3. Antiemetics
- 10.2.4. Bisphosphonates
- 10.2.5. Opioids
- 10.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- 10.2.7. Others (Topicals, etc.)
10.3. Market Value Forecast By Indication, 2017-2031
- 10.3.1. Lung Cancer
- 10.3.2. Breast Cancer
- 10.3.3. Prostate Cancer
- 10.3.4. Liver Cancer
- 10.3.5. Bladder Cancer
- 10.3.6. Leukemia
- 10.3.7. Others (Ovarian Cancer, Melanoma, etc.)
10.4. Market Value Forecast By Distribution Channel, 2017-2031
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Others (Compounding Pharmacies, etc.)
10.5. Market Value Forecast By Country, 2017-2031
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Drug Class
- 10.6.2. By Indication
- 10.6.3. By Distribution Channel
- 10.6.4. By Country

11. Europe Cancer Supportive Care Drugs Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast By Drug Class, 2017-2031
- 11.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
- 11.2.2. ESAs (Erythropoiesis Stimulating Agent)
- 11.2.3. Antiemetics
- 11.2.4. Bisphosphonates
- 11.2.5. Opioids
- 11.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- 11.2.7. Others (Topicals, etc.)
11.3. Market Value Forecast By Indication, 2017-2031
- 11.3.1. Lung Cancer
- 11.3.2. Breast Cancer
- 11.3.3. Prostate Cancer
- 11.3.4. Liver Cancer
- 11.3.5. Bladder Cancer
- 11.3.6. Leukemia
- 11.3.7. Others (Ovarian Cancer, Melanoma, etc.)
11.4. Market Value Forecast By Distribution Channel, 2017-2031
- 11.4.1. Hospital Pharmacies
- 11.4.2. Retail Pharmacies
- 11.4.3. Others (Compounding Pharmacies, etc.)
11.5. Market Value Forecast By Country, 2017-2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
- 11.6.1. By Drug Class
- 11.6.2. By Indication
- 11.6.3. By Distribution Channel
- 11.6.4. By Country

12. Asia Pacific Cancer Supportive Care Drugs Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast By Drug Class, 2017-2031
- 12.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
- 12.2.2. ESAs (Erythropoiesis Stimulating Agent)
- 12.2.3. Antiemetics
- 12.2.4. Bisphosphonates
- 12.2.5. Opioids
- 12.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- 12.2.7. Others (Topicals, etc.)
12.3. Market Value Forecast By Indication, 2017-2031
- 12.3.1. Lung Cancer
- 12.3.2. Breast Cancer
- 12.3.3. Prostate Cancer
- 12.3.4. Liver Cancer
- 12.3.5. Bladder Cancer
- 12.3.6. Leukemia
- 12.3.7. Others (Ovarian Cancer, Melanoma, etc.)
12.4. Market Value Forecast By Distribution Channel, 2017-2031
- 12.4.1. Hospital Pharmacies
- 12.4.2. Retail Pharmacies
- 12.4.3. Others (Compounding Pharmacies, etc.)
12.5. Market Value Forecast By Country, 2017-2031
- 12.5.1. China
- 12.5.2. India
- 12.5.3. Japan
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
- 12.6.1. By Drug Class
- 12.6.2. By Indication
- 12.6.3. By Distribution Channel
- 12.6.4. By Country

13. Latin America Cancer Supportive Care Drugs Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class, 2017-2031
- 13.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
- 13.2.2. ESAs (Erythropoiesis Stimulating Agent)
- 13.2.3. Antiemetics
- 13.2.4. Bisphosphonates
- 13.2.5. Opioids
- 13.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- 13.2.7. Others (Topicals, etc.)
13.3. Market Value Forecast By Indication, 2017-2031
- 13.3.1. Lung Cancer
- 13.3.2. Breast Cancer
- 13.3.3. Prostate Cancer
- 13.3.4. Liver Cancer
- 13.3.5. Bladder Cancer
- 13.3.6. Leukemia
- 13.3.7. Others (Ovarian Cancer, Melanoma, etc.)
13.4. Market Value Forecast By Distribution Channel, 2017-2031
- 13.4.1. Hospital Pharmacies
- 13.4.2. Retail Pharmacies
- 13.4.3. Others (Compounding Pharmacies, etc.)
13.5. Market Value Forecast By Country, 2017-2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
- 13.6.1. By Drug Class
- 13.6.2. By Indication
- 13.6.3. By Distribution Channel
- 13.6.4. By Country

14. Middle East & Africa Cancer Supportive Care Drugs Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast By Drug Class, 2017-2031
- 14.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
- 14.2.2. ESAs (Erythropoiesis Stimulating Agent)
- 14.2.3. Antiemetics
- 14.2.4. Bisphosphonates
- 14.2.5. Opioids
- 14.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- 14.2.7. Others (Topicals, etc.)
14.3. Market Value Forecast By Indication, 2017-2031
- 14.3.1. Lung Cancer
- 14.3.2. Breast Cancer
- 14.3.3. Prostate Cancer
- 14.3.4. Liver Cancer
- 14.3.5. Bladder Cancer
- 14.3.6. Leukemia
- 14.3.7. Others (Ovarian Cancer, Melanoma, etc.)
14.4. Market Value Forecast By Distribution Channel, 2017-2031
- 14.4.1. Hospital Pharmacies
- 14.4.2. Retail Pharmacies
- 14.4.3. Others (Compounding Pharmacies, etc.)
14.5. Market Value Forecast By Country, 2017-2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
- 14.6.1. By Drug Class
- 14.6.2. By Indication
- 14.6.3. By Distribution Channel
- 14.6.4. By Country

15. Competition Landscape

15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
- 15.3.1. Amgen, Inc.
  - 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.1.2. Material Portfolio
  - 15.3.1.3. Financial Overview
  - 15.3.1.4. SWOT Analysis
  - 15.3.1.5. Strategic Overview
- 15.3.2. Merck & Co., Inc.
  - 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.2.2. Material Portfolio
  - 15.3.2.3. Financial Overview
  - 15.3.2.4. SWOT Analysis
  - 15.3.2.5. Strategic Overview
- 15.3.3. Johnson & Johnson Services, Inc.
  - 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.3.2. Material Portfolio
  - 15.3.3.3. Financial Overview
  - 15.3.3.4. SWOT Analysis
  - 15.3.3.5. Strategic Overview
- 15.3.4. Heron Therapeutics, Inc.
  - 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.4.2. Material Portfolio
  - 15.3.4.3. Financial Overview
  - 15.3.4.4. SWOT Analysis
  - 15.3.4.5. Strategic Overview
- 15.3.5. Novartis AG
  - 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.5.2. Material Portfolio
  - 15.3.5.3. Financial Overview
  - 15.3.5.4. SWOT Analysis
  - 15.3.5.5. Strategic Overview
- 15.3.6. GSK plc
  - 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.6.2. Material Portfolio
  - 15.3.6.3. Financial Overview
  - 15.3.6.4. SWOT Analysis
  - 15.3.6.5. Strategic Overview
- 15.3.7. F. Hoffmann-La Roche Ltd.
  - 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.7.2. Material Portfolio
  - 15.3.7.3. Financial Overview
  - 15.3.7.4. SWOT Analysis
  - 15.3.7.5. Strategic Overview
- 15.3.8. Helsinn Healthcare SA
  - 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.8.2. Material Portfolio
  - 15.3.8.3. Financial Overview
  - 15.3.8.4. SWOT Analysis
  - 15.3.8.5. Strategic Overview